Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis

OBJECTIVE: Evaluate relationship between radiographic progression and clinical outcomes in post hoc analyses of patients with psoriatic arthritis (PsA) receiving up to 2 years of guselkumab therapy in the phase 3, placebo-controlled, randomised trial, DISCOVER-2. METHODS: Biologic-naïve adults with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gottlieb, Alice B, McInnes, Iain B, Rahman, Proton, Kollmeier, Alexa P, Xu, Xie L, Jiang, Yusang, Sheng, Shihong, Shawi, May, Chakravarty, Soumya D, Lavie, Frederic, Mease, Philip J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972414/
https://www.ncbi.nlm.nih.gov/pubmed/36828643
http://dx.doi.org/10.1136/rmdopen-2022-002789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972414/
https://www.ncbi.nlm.nih.gov/pubmed/36828643
http://dx.doi.org/10.1136/rmdopen-2022-002789

Ejemplares similares